Search

Your search keyword '"Fornasiero, Arianna"' showing total 32 results

Search Constraints

Start Over You searched for: Author "Fornasiero, Arianna" Remove constraint Author: "Fornasiero, Arianna"
32 results on '"Fornasiero, Arianna"'

Search Results

1. Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study

2. Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients

3. A “Candidate-Interactome” Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis

4. Bacille Calmette-Guérin (BCG) Vaccine in Neuroinflammation

5. Contributors

6. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

7. Contributors

8. Chemical Elements and Oxidative Status in Neuroinflammation

9. Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Dimethylfumarate

10. Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study

13. The Contribution of Gut Barrier Changes to Multiple Sclerosis Pathophysiology

14. Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority

15. Genome-Wide Multiple Sclerosis Association Data and Coagulation

17. Fingolimod vs dimethyl fumarate in multiple sclerosis

18. Corrigendum to “Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia” [Clin. Neurol. Neurosurg. 168 (May) (2018) 60–63]

21. Rhizome

22. Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study

23. IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status

29. Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study.

30. Epstein-Barr virus genetic variants are associated with multiple sclerosis.

31. Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

32. Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.

Catalog

Books, media, physical & digital resources